Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03424005
Previous Study | Return to List | Next Study

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03424005
Recruitment Status : Recruiting
First Posted : February 6, 2018
Last Update Posted : May 6, 2020
Sponsor:
Collaborators:
Seattle Genetics, Inc.
Immunomedics, Inc.
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE January 30, 2018
First Posted Date  ICMJE February 6, 2018
Last Update Posted Date May 6, 2020
Actual Study Start Date  ICMJE April 2, 2018
Estimated Primary Completion Date May 12, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 8, 2020)
  • Objective Response Rate (ORR) [ Time Frame: Baseline until disease progression or loss of clinical benefit (approximately 5 years) ]
  • Number of Participants With Adverse Events [ Time Frame: Baseline to end of study (approximately 5 years) ]
Original Primary Outcome Measures  ICMJE
 (submitted: February 5, 2018)
Objective Response Rate (ORR) [ Time Frame: Baseline until disease progression or loss of clinical benefit ( approximately 4 years) ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 8, 2020)
  • Progression Free Survival (PFS) [ Time Frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years) as determined by the investigator according to RECIST v1.1 ]
  • Disease Control Rate (DCR) [ Time Frame: Baseline through end of study (approximately 5 years) ]
  • Overall Survival (OS) [ Time Frame: Randomization to death from any cause, through the end of study (approximately 5 years) ]
  • Overall Survival (at specific time-points) [ Time Frame: 12 and 18 months ]
  • Duration of Response (DOR) [ Time Frame: Randomization until first occurrence of a documented objective response to the first recorded occurrence of disease progression or death from any cause (whichever occurs first), through end of study (approximately 5 years) ]
  • Serum Concentration of Atezolizumab [ Time Frame: Day 1, Cycle 1: pre-treatment and 30 mins post-infusion; Day 1 of Cycles 2,3,4,8,12, and 16: pre-treatment (Cycles = 21 or 28 days); through end of study (~ 5 years); 120 days after last dose ]
  • Plasma Concentration of Ipatasertib [ Time Frame: Day 15, Cycle 1: pre treatment and 1-3 hours after Ipatasertib dose (Cycle = 28 days) ]
  • Plasma or Serum Concentration of SGN-LIV1A [ Time Frame: Day 1 Cycles 1-2: pre-treatment and 30 minutes after SGN-LIV1A infusion; Days 8 and 15, Cycle 1 at visit; Day 1 of Cycles 3, 4, 8, 12, and 16 pretreatment (Cycle = 21 days); 30 days after last dose of SGN-LIV1A; 120 days after last dose of atezolizumab ]
  • Serum Concentration of Selicrelumab [ Time Frame: Pre-treatment on Day 1 of Cycles 1, 2, 4, 8, 12, and 16 (Cycle = 28 days); 30 days after last dose ]
  • Serum Concentration of Bevacizumab [ Time Frame: Pre-treatment on Day 1 of Cycles 1 and 4 (Cycles = 21 or 28 days); 30 days after last dose ]
  • Serum Concentration of Tocilizumab [ Time Frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, and 16 pre-treatment (Cycle = 28 days); 30 days after last dose ]
  • Serum Concentration of Sacituzumab Govitecan [ Time Frame: Day 1 of Cycles 1, 3 5, 7, 9, and 11 and every third cycle thereafter pre-treatment and 30 minutes after sacituzumab govitecan infusion (Cycle = 21 days); 30 days after last dose ]
Original Secondary Outcome Measures  ICMJE
 (submitted: February 5, 2018)
  • Progression Free Survival (PFS) [ Time Frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 4 years) as determined by the investigator according to RECIST v1.1 ]
  • Disease Control Rate (DCR) [ Time Frame: Baseline through end of study (approximately 4 years) ]
  • Overall Survival (OS) [ Time Frame: Randomization to death from any cause, through the end of study (approximately 4 years) ]
  • Overall Survival (at specific time-points) [ Time Frame: 12 and 18 months ]
  • Duration of Response (DOR) [ Time Frame: Randomization until first occurrence of a documented objective response to the first recorded occurrence of disease progression or death from any cause (whichever occurs first), through end of study (approximately 4 years) ]
  • Percentage of Participants with Adverse Events [ Time Frame: Baseline to end of study (approximately 4 years) ]
  • Serum Concentration of Atezolizumab [ Time Frame: Day 1, Cycle 1 pre-treatment and 30 mins post-infusion; Day 1 of Cycles 2,3,4,8,12, and 16 pre-treatment; through end of study (~ 4 years); 120 days after last dose ]
  • Plasma Concentration of Ipatasertib [ Time Frame: Day 15, Cycle 1 pre treatment and 1-3 hours after Ipatasertib dose; ]
  • Plasma or Serum Concentration of SNG-LIV1A [ Time Frame: Day 1 Cycle, 1 pre-treatment and 30 minutes after SGN-LIV1A infusion ]
  • Plasma Concentration of Cobimetinib [ Time Frame: Day 15, Cycle 1 Pre- Cobimetinib dose and 2-4 hours after Cobimetinib dose ]
  • Plasma Concentration of Capecitabine [ Time Frame: Day 1, Cycle 1, 2 hours after capecitabine dose ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer
Official Title  ICMJE A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Brief Summary

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced TNBC.

The study will be performed in two stages. During Stage 1, two cohorts will be enrolled in parallel in this study: one cohort will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line [1L] PD-L1+ cohort), and one cohort will consist of participants who had disease progression during or following 1L treatment with chemotherapy (e.g., paclitaxel, nab-paclitaxel, carboplatin) and have not received cancer immunotherapy (CIT) (second-line [2L] CIT-naive cohort). In addition, participants in the 2L CIT-naive cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination (Stage 2), provided Stage 2 is open for enrollment.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Triple Negative Breast Cancer
Intervention  ICMJE
  • Drug: Capecitabine
    Capecitabine will be administered 1250 mg/m^2 orally twice daily on Days 1−14, of each 21 day cycle.
  • Drug: Atezolizumab

    For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.

    For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle.

  • Drug: Ipatasertib
    Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
  • Drug: SGN-LIV1A
    SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
  • Drug: Bevacizumab
    Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
  • Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)

    Gemcitabine will be administered by IV, 1000 mg/m^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.

    Or

    Eribulin will be administered by IV, 1.4 mg/m^2 on days 1 and 8 of each 21 day cycle.

  • Drug: Selicrelumab
    Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
  • Drug: Tocilizumab
    Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
  • Drug: Nab-Paclitaxel
    Nab-Paclitaxel will be administered by IV, 100 mg/m^2, on Days 1, 8, and 15 of each 28-day cycle.
  • Drug: Sacituzumab Govitecan
    Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
Study Arms  ICMJE
  • Active Comparator: Atezolizumab + Nab-Paclitaxel
    1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab + nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    Interventions:
    • Drug: Atezolizumab
    • Drug: Nab-Paclitaxel
  • Experimental: Atezolizumab + Nab-Paclitaxel + Tocilizumab
    1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    Interventions:
    • Drug: Atezolizumab
    • Drug: Tocilizumab
    • Drug: Nab-Paclitaxel
  • Experimental: Atezolizumab + Sacituzumab Govitecan
    1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    Interventions:
    • Drug: Atezolizumab
    • Drug: Sacituzumab Govitecan
  • Active Comparator: Capecitabine

    2L CIT-naive participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).

    Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.

    Intervention: Drug: Capecitabine
  • Experimental: Atezolizumab + Ipatasertib

    2L CIT-naive participants will receive doublet combination treatment with atezolizumab + ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

    Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.

    Interventions:
    • Drug: Atezolizumab
    • Drug: Ipatasertib
  • Experimental: Atezolizumab + SGN-LIV1A

    2L CIT-naive participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

    Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.

    Interventions:
    • Drug: Atezolizumab
    • Drug: SGN-LIV1A
  • Experimental: Atezolizumab + Selicrelumab + Bevacizumab

    2L-CIT-naive participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

    Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.

    Interventions:
    • Drug: Atezolizumab
    • Drug: Bevacizumab
    • Drug: Selicrelumab
  • Experimental: Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)
    2L CIT-naive participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naive participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemotherapy (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    Interventions:
    • Drug: Atezolizumab
    • Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 8, 2020)
280
Original Estimated Enrollment  ICMJE
 (submitted: February 5, 2018)
260
Estimated Study Completion Date  ICMJE May 12, 2023
Estimated Primary Completion Date May 12, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria Stage 1

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Metastatic or inoperable locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
  • For the 1L PD L1+ cohort: no prior systemic treatment for metastatic or inoperable locally advanced TNBC
  • For the 2L CIT-naive cohort: Eligible for capecitabine monotherapy
  • For the 2L CIT-naive cohort: Radiologic/objective evidence of recurrence or disease progression after 1L treatment with chemotherapy, for a total of one line of therapy for inoperable locally advanced or metastatic breast cancer
  • Life expectancy =/> 3 months, as determined by the investigator
  • Availability of a representative tumor specimen that is suitable for determination of PD-L1 and/or additional biomarker status via central testing
  • For the 1L PD L1+ cohort: Positive PD-L1 expression, defined as >/= 1% of the tumor area occupied by PD L1-expressing tumor-infiltrating immune cells of any intensity, as determined through use of the U.S. Food and Drug Administration-approved or CE-marked Ventana PD-L1 (SP142) Assay

Inclusion Criteria for Stage 1 (both cohorts) and Stage 2 (2L CIT-naive cohort)

  • Measurable disease (at least one target lesion)
  • Tumor accessible for biopsy
  • Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.
  • Negative HIV test at screening
  • Negative hepatitis B surface antigen test
  • Negative total hepatitis B core antibody (HBcAb)
  • Negative hepatitis C virus (HCV) antibody test at screening
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from breastfeeding and donating eggs as outlined for each specific treatment arm
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm

Inclusion Criteria Stage 2 (2L CIT-naive cohort)

  • ECOG Performance Status of 0, 1, or 2
  • Patients randomly allocated to the control arm during Stage 1: ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity, provided that Medical Monitor approval for entry into Stage 2 is obtained, or disease progression per RECIST v1.1 while receiving control treatment
  • Patients randomly allocated to an experimental arm during Stage 1: ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity not related to atezolizumab, disease progression per RECIST v1.1, or loss of clinical benefit as determined by the investigator while receiving Stage 1 treatment
  • Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1 (if deemed clinically feasible by the investigator)

Exclusion Criteria for Stage 1

  • Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, CD40 agonists or interleukin-2 (IL-2) or IL-2-like compounds
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Biologic treatment (e.g., bevacizumab) within 2 weeks prior to initiation of study treatment, or other systemic treatment for TNBC within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade </= 1 or better with the exception of alopecia of any grade and Grade </= 2 peripheral neuropathy
  • Eligibility only for the control arm

Exclusion Criteria for Stage 1 (both cohorts) and Stage 2 (2L CIT-naïve cohort)

  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Uncontrolled tumor-related pain
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of leptomeningeal disease
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • Significant cardiovascular disease
  • Prior allogeneic stem cell or solid organ transplantation
  • History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
  • Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study

Exclusion Criteria for the 2L CIT-naive cohort, Stage 1

  • Prior treatment with capecitabine,
  • Treatment with sorivudine or its chemically related analogues, such as brivudine
  • History of severe and unexpected reactions to fluoropyrimidine therapy
  • Known complete absence of dihydropyrimidine dehydrogenase activity

Exclusion Criteria for Stage 2

  • Inability to tolerate atezolizumab during Stage 1
  • For patients receiving eribulin: congenital long QT syndrome

Additional drug-specific exclusion criteria may apply to Stage 1 and 2

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Reference Study ID Number: CO40115 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com
Listed Location Countries  ICMJE Australia,   France,   Germany,   Korea, Republic of,   Spain,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03424005
Other Study ID Numbers  ICMJE CO40115
2017-002038-21 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Hoffmann-La Roche
Study Sponsor  ICMJE Hoffmann-La Roche
Collaborators  ICMJE
  • Seattle Genetics, Inc.
  • Immunomedics, Inc.
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP